経動脈的化学塞栓療法の市場規模、シェア、成長分析：手技タイプ別、製品タイプ別、適応症別、エンドユーザー別、地域別 - 産業予測 2025～2032年

経動脈的化学塞栓療法（TACE）市場規模は2023年に102億米ドルと評価され、2024年の106億6,000万米ドルから2032年には151億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.5%で成長する見通しです。

世界の経動脈的化学塞栓療法（TACE）市場は、肝炎感染、アルコール使用、非アルコール性脂肪性肝疾患などの要因による肝がん有病率の上昇に対応し、肝腫瘍治療への低侵襲的アプローチにより消費者の嗜好に変化が生じています。医療技術の革新により、TACEの手技がより洗練され、精度が向上し、コストが削減されたため、需要が高まっています。肝がんの症状や早期診断の重要性に関する意識の高まりは、特に中悪性度の症例において、患者が早期に治療を受けるよう促しています。しかし、市場力学は地域によって異なり、医療インフラ、リスク要因の発生率、規制の枠組みなどに影響されます。特に中国をはじめとするアジア太平洋地域では、肝臓がんの発生率が高いことから大きな成長が観察されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

経動脈的化学塞栓療法市場規模：手技タイプ別& CAGR（2025-2032）

• 市場概要
• 従来のTACE
• DEB-TACE

経動脈的化学塞栓療法市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• 化学療法
• 放射線治療薬
• 薬剤溶出粒子

経動脈的化学塞栓療法市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 切除不能肝細胞がん
• 早期肝細胞がん

経動脈的化学塞栓療法市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• がん研究センター

経動脈的化学塞栓療法市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Meril Life Sciences（India）
• MicroPort（China）
• Terumo Corporation（Japan）
• Ethicon（Johnson & Johnson）（United States）
• Neusoft Medical Systems Co., Ltd.（China）
• Merit Medical Systems, Inc.（United States）
• Guerbet Group（France）
• AngioDynamics, Inc.（United States）
• Boston Scientific（United States）
• Medtronic（Ireland）
• Beckton Dickinson（United States）
• Cook Group（United States）
• HealthTronics（United States）
• IceCure Medical（Israel）
• Profound Medical（Canada）
• Siemens Healthineers（Germany）
• GE Healthcare（United States）
• Philips Healthcare（Netherlands）
• Sirtex Medical（Australia）
• BTG plc（United Kingdom）

結論と提言

Transarterial Chemoembolization Market size was valued at USD 10.2 billion in 2023 and is poised to grow from USD 10.66 billion in 2024 to USD 15.16 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global transarterial chemoembolization (TACE) market is experiencing a shift in consumer preferences due to its minimally invasive approach to treating hepatoma, in response to the rising prevalence of liver cancer driven by factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease. Innovations in medical technology have led to more sophisticated TACE procedures, enhancing accuracy and reducing costs, thereby boosting demand. Increased awareness regarding liver cancer symptoms and the importance of early diagnosis is prompting patients to seek treatment earlier, particularly for intermediate-grade cases. However, market dynamics vary by region, influenced by healthcare infrastructure, risk factor incidence, and regulatory frameworks, with significant growth observed in the Asia-Pacific region due to higher liver cancer rates, notably in China.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transarterial Chemoembolization Market Segments Analysis

Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is being propelled by the rising global prevalence of liver cancer, which necessitates effective treatment options. In addition, advancements in medical technology are enhancing the precision and effectiveness of these therapeutic procedures, influencing both healthcare providers and patients to opt for TACE. The appeal of minimally invasive techniques plays a significant role in the growth of this market, as they minimize discomfort and pain compared to conventional treatment approaches. As the demand for innovative and less intrusive cancer treatment continues to grow, TACE is emerging as a favored choice among patients and oncologists alike.

Restraints in the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market faces significant challenges stemming from the diverse nature of liver cancer patients and their varied responses to treatment. This complexity necessitates a tailored approach to TACE, hindering its widespread adoption. Additionally, stringent regulations surrounding the approval and reimbursement of medical procedures further constrain market growth. Variations in reimbursement policies and lengthy regulatory approval processes can impede the integration of TACE into standard healthcare practices, ultimately limiting its accessibility and use among patients. Consequently, these factors collectively act as significant restraints on the TACE market, affecting its overall development and implementation.

Market Trends of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is witnessing a significant trend towards personalized medicine, which emphasizes tailored treatment approaches for liver cancer patients. Healthcare providers are increasingly exploring customized TACE strategies based on individual patient characteristics, overall health status, and specific tumor types. This shift aligns with the broader movement toward precision medicine, aiming to optimize patient outcomes through bespoke therapies. Additionally, technological innovations are revolutionizing the TACE landscape, with ongoing research focused on enhancing the precision and efficacy of treatment. Advances in embolic agents, drug-eluting bead technologies, and imaging tools are enabling more targeted interventions, ensuring that the therapeutic impact on cancerous tissues is maximized while minimizing harm to surrounding healthy organs. This dual trend of personalization and technology integration is poised to drive growth in the TACE market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2025-2032)

• Market Overview
• Conventional TACE
• DEB-TACE

Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Global Transarterial Chemoembolization Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Unresectable HCC
• Early-Stage HCC

Global Transarterial Chemoembolization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers

Global Transarterial Chemoembolization Market Size & CAGR (2025-2032)

• North America (Procedure Type, Product Type, Indication, End-User)
  • US
  • Canada
• Europe (Procedure Type, Product Type, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Procedure Type, Product Type, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Procedure Type, Product Type, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Meril Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon (Johnson & Johnson) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neusoft Medical Systems Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckton Dickinson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Group (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HealthTronics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IceCure Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profound Medical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirtex Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations